Advertisement
Screener

Shattuck Labs, Inc. (STTK) Return on Tangible Equity

2.8 / 5 stars · 68/120 Roast Me

Shattuck Labs, Inc. Return Tang Equity

Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Shattuck Labs, Inc. return tang equity for the quarter ending 2026-06-30 was -24.90%, a change of 82.99% year-over-year.
  • Shattuck Labs, Inc. return tang equity for the quarter ending 2026-03-31 was -52.04%, a change of 52.43% year-over-year.
  • Shattuck Labs, Inc. return tang equity for the quarter ending 2025-12-31 was -59.24%, a change of 35.46% year-over-year.
  • Shattuck Labs, Inc. return tang equity for the quarter ending 2025-09-30 was -58.87%, a change of 18.18% year-over-year.
  • Shattuck Labs, Inc. return tang equity for fiscal 2025 was -59.24%, a change of 35.46% from fiscal 2024.
  • Shattuck Labs, Inc. return tang equity for fiscal 2024 was -94.71%, a change of -34.38% from fiscal 2023.
  • Shattuck Labs, Inc. return tang equity for fiscal 2023 was -60.33%, a change of -2.46% from fiscal 2022.
  • Shattuck Labs, Inc. return tang equity for fiscal 2022 was -57.87%, a change of -41.32% from fiscal 2021.
Available history
2019-12-31 to 2026-06-30
Data captured

Historical Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2026-06-30-24.90%-$52.57M$211.14M
2026-03-31-52.04%-$49.87M$95.84M
2025-12-31-59.24%-$48.81M$82.39M
2025-09-30-58.87%-$54.9M$93.24M
2025-06-30-107.88%-$61.51M$57.02M
2025-03-31-104.47%-$70.61M$67.59M
2024-12-31-94.71%-$75.41M$79.63M
2024-09-30-77.06%-$74.42M$96.58M
2024-06-30-77.10%-$85.28M$110.62M
2024-03-31-66.05%-$85.08M$128.81M
2023-12-31-60.33%-$87.3M$144.71M
2023-09-30-84.25%-$95.02M$112.78M
2023-06-30-66.53%-$92.12M$138.46M
2023-03-31-62.25%-$98.14M$157.65M
2022-12-31-57.87%-$101.95M$176.16M
2022-09-30-34.44%-$68.69M$199.42M
2022-06-30-27.62%-$61.46M$222.53M
2022-03-31-23.17%-$57.69M$248.94M
2021-12-31-16.55%-$44.97M$271.79M
2021-09-30-24.82%-$64.83M$261.17M
2021-06-30-21.38%-$59.25M$277.09M
2021-03-31-14.02%-$41.86M$298.66M
2020-12-31-11.81%-$36.6M$309.86M
2020-09-3054.76%-$31.96M-$58.36M
2020-06-3058.28%-$27.41M-$47.03M
2020-03-3166.29%-$27.09M-$40.86M
2019-12-3169.42%-$23.98M-$34.55M

Annual Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2025-12-31-59.24%-$48.81M$82.39M
2024-12-31-94.71%-$75.41M$79.63M
2023-12-31-60.33%-$87.3M$144.71M
2022-12-31-57.87%-$101.95M$176.16M
2021-12-31-16.55%-$44.97M$271.79M
2020-12-31-11.81%-$36.6M$309.86M
2019-12-3169.42%-$23.98M-$34.55M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Neurogene Inc. (NGNE)$0.625B-4.46
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
IMPACT BIOMEDICAL INC. (IBO)United States$0.611B66.47
Aquestive Therapeutics, Inc. (AQST)United States$0.606B-6.67
CorMedix Inc. (CRMD)United States$0.605B3.25
ZEVRA THERAPEUTICS, INC. (ZVRA)United States$0.668B14.61
CytomX Therapeutics, Inc. (CTMX)United States$0.598B-10.25
Monopar Therapeutics (MNPR)United States$0.598B-34.82
Altimmune, Inc. (ALT)United States$0.593B-6.43
Climb Bio, Inc. (CLYM)United States$0.683B-13.03